EUVIMEDEUVIMED entdecken
Open Access

HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation

Shuai Yan, Lu Chen, Hao Zhuang, Hui Yang, Yinmo Yang, Ning Zhang, Rong Liu

International Journal of Biological Sciences · 2024 · 20 (8) · 3046-3060

DOI: 10.7150/ijbs.93375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Shuai Yan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Carcinoma, Hepatocellular, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesPhenylurea CompoundsCarcinoma, HepatocellularHistone Deacetylase InhibitorsLiver NeoplasmsProto-Oncogene Proteins c-aktHumansCell Line, TumorApoptosisCell ProliferationAnimalsVorinostatDrug SynergismMiceDrug Resistance, Neoplasm

Stichwörter der Autor:innen

AKTHepatocellular carcinomaLenvatinib resistanceSAHAcombination treatment

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsHistone Deacetylase InhibitorsProto-Oncogene Proteins c-aktVorinostat

Autor:innen und Institutionen

  • Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China.
  • Department of Hepatobiliary Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
  • Department of Hepatic Biliary Pancreatic Surgery, Henan Cancer Hospital, Zhengzhou 450000, China.
  • Department of General Surgery, Peking University First Hospital, Beijing 100034, China.
  • International Cancer Institute, Peking University Health Science Center, Beijing 100191, China.
  • Yunnan Baiyao Group, Kunming 650504, China.

Zitieren

APA

Yan, S., Chen, L., Zhuang, H., Yang, H., Yang, Y., Zhang, N., & Liu, R. (2024). HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation. International Journal of Biological Sciences, 20(8), 3046-3060. https://doi.org/10.7150/ijbs.93375

Vancouver

Yan S, Chen L, Zhuang H, Yang H, Yang Y, Zhang N, et al. HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation. International Journal of Biological Sciences. 2024;20(8):3046-3060. doi:10.7150/ijbs.93375

BibTeX
@article{Yan2024,
  author = {Yan, Shuai and Chen, Lu and Zhuang, Hao and Yang, Hui and Yang, Yinmo and Zhang, Ning and Liu, Rong},
  title = {HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation},
  journal = {International Journal of Biological Sciences},
  year = {2024},
  volume = {20},
  number = {8},
  pages = {3046--3060},
  doi = {10.7150/ijbs.93375}
}
Kostenlos starten →